Shumail Haque, DO
Pain Medicine · Levittown, NYNPI 1144636754
Payments from drug & device makers
Across 344 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pacira Pharmaceuticals Incorporated$759
- Scilex Pharmaceuticals Inc.$596
- Indivior Inc.$417
- Collegium Pharmaceutical, Inc.$392
- Valinor Pharma, LLC$382
- plus $3K from 30 others
What the payments were for
- Travel & lodging$6359%
- Food & beverage$6,26191%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,422 |
| Pacira Pharmaceuticals Incorporated | 5 | $759 |
| Scilex Pharmaceuticals Inc. | 30 | $596 |
| Indivior Inc. | 21 | $417 |
| Collegium Pharmaceutical, Inc. | 25 | $392 |
| Valinor Pharma, LLC | 45 | $382 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $294 |
| Vertex | 9 | $226 |
| MDD US Operations, LLC | 10 | $204 |
| Abbott | 5 | $188 |
| Arbor Pharmaceuticals, Inc. | 12 | $177 |
| Bioventus LLC | 6 | $157 |
| Forte Bio-pharma LLC | 2 | $152 |
| Azurity Pharmaceuticals, Inc. | 8 | $151 |
| Orexo US, Inc. | 8 | $142 |
| Daiichi Sankyo Inc. | 10 | $140 |
| Biohaven Pharmaceuticals, Inc. | 6 | $136 |
| Pfizer | 7 | $129 |
| Redhill Biopharma Inc. | 8 | $122 |
| Axsome Therapeutics, Inc. | 4 | $103 |
| Braeburn Inc. | 4 | $97 |
| Protega Pharmaceutials Inc | 5 | $95 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $87 |
| Medtronic | 3 | $58 |
| Virtus Pharmaceuticals LLC | 3 | $57 |
| Si-bone, Inc. | 1 | $38 |
| Saluda Medical Americas, Inc. | 1 | $27 |
| Eisai Inc. | 2 | $26 |
| Biodelivery Sciences International, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Shionogi Inc | 1 | $15 |
| Pernix Therapeutics Holdings, Inc. | 1 | $14 |
| Kaleo, Inc. | 1 | $11 |
| Sentynl Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,896 in reported general payments places this provider in the 75th percentile of 503 pain medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Budesonide ErBudesonide | 189 | $642,579 |
| OxycontinOxycodone Hcl | 181 | $145,921 |
| RelistorMethylnaltrexone Bromide | 23 | $55,694 |
| MovantikNaloxegol Oxalate | 127 | $54,878 |
| Xtampza ErOxycodone Myristate | 77 | $54,551 |
| Nurtec OdtRimegepant Sulfate | 20 | $38,564 |
| Diclofenac Sodium | 220 | $37,312 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 855 | $31,665 |
| ZtlidoLidocaine | 42 | $27,190 |
| Fentanyl Citrate | 27 | $26,211 |
| Oxycodone Hcl | 899 | $18,339 |
| LinzessLinaclotide | 25 | $15,061 |
| BelbucaBuprenorphine Hcl | 27 | $14,227 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 98 | $12,858 |
| Nucynta ErTapentadol Hcl | 14 | $12,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er | $392 | $81,071118 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $294 | $55,69423 claims |
| Redhill Biopharma Inc.Movantik | $122 | $54,878127 claims |
| PfizerNurtec Odt | $129 | $38,56420 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $596 | $27,19042 claims |
| AbbVieLinzess | $1,422 | $15,06125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 503 pain medicine providers in New York.
Other pain medicine in Levittown
- Gary SchwartzBrooklyn$756K
- Amitabh GulatiNew York$627K
- William CaldwellStony Brook$550K
- Brian DurkinPort Jefferson$459K
- Grace FordeNew Hyde Park$398K
- David SpinnerNew York$391K
- John MarkmanRochester$300K
- Naum ShaparinBronx$178K
- Ashraf HenryAmherst$168K
- Kenneth ChapmanStaten Island$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.